13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001822947
Total reported value
$113.1M
$113.1M
28 檔
39.6%
As reported in its official Q1 2025 Form 13F filing, Ally Bridge Group's tracked investment portfolio stood at $113.1M with 28 total positions.
In Q1 2025, Ally Bridge Group displayed an active expansion posture, initiating 28 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including SWTXUSD, VRNA, SLNOEUR) accounted for 39.6% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 11.18% | — | +414.04% | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 7.96% | — | — | |
| 3 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 7.76% | -10.82% | EXIT | |
| 4 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 7.58% | +3.57% | NEW | |
| 5 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 5.92% | -4.58% | EXIT | |
| 6 | 2655787D | Blueprint Medicines CORP | Stock-Other | 5.92% | — | +32.74% | |
| 7 | INSM | Insmed Inc | Stock-Healthcare | 5.85% | — | -25.58% | |
| 8 | ✓ | Axsome Therapeutics Inc | Stock-Other | 5.26% | — | — | |
| 9 | TRVI | Trevi Therapeutics Inc | Stock-Other | 3.89% | — | -12.19% | |
| 10 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.26% | -8.54% | EXIT | |
| 11 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.15% | — | -0.59% | |
| 12 | ELVN | Enliven Therapeutics Inc | Stock-Other | 3.01% | — | +19.80% | |
| 13 | ✓ | Merus N V | Stock-Other | 2.96% | — | -33.31% | |
| 14 | GERN | Geron CORP | Stock-Other | 2.95% | — | +91.35% | |
| 15 | CGON | Cg Oncology Inc | Stock-Other | 2.92% | — | -23.99% | |
| 16 | ATYR | Atyr Pharma Inc | Stock-Other | 2.12% | — | +11.05% | |
| 17 | TECX | Tectonic Therapeutic Inc | Stock-Other | 2.11% | — | — | |
| 18 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.11% | — | -46.17% | |
| 19 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 2.06% | — | +18.13% | |
| 20 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.04% | -1.11% | +23.41% | |
| 21 | ✓ | Edgewise Therapeutics Inc | Stock-Other | 1.98% | — | — | |
| 22 | JANX | Janux Therapeutics Inc | Stock-Other | 1.98% | — | -9.97% | |
| 23 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.32% | — | -24.29% | |
| 24 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 1.31% | +1.03% | — | |
| 25 | KRRO | Korro Bio Inc | Stock-Other | 0.94% | — | -15.50% | |
| 26 | PMNEUR | Promis Neurosciences Inc | Stock-Other | 0.93% | — | -6.78% | |
| 27 | TYRA | Tyra Biosciences Inc | Stock-Other | 0.90% | — | -38.74% | |
| 28 | CNTX | Context Therapeutics Inc | Stock-Other | 0.64% | — | -26.59% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SWTXUSD | Springworks Therapeutics Inc | — | NEW | New buy |
| 2 | VRNA | Verona Pharma PLC - Adr | — | NEW | New buy |
| 3 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 4 | AXSM | Axsome Therapeutics Inc | — | NEW | New buy |
| 5 | TARS | Tarsus Pharmaceuticals Inc | — | NEW | New buy |
| 6 | 2655787D | Blueprint Medicines CORP | — | NEW | New buy |
| 7 | INSM | Insmed Inc | — | NEW | New buy |
| 8 | ✓ | Axsome Therapeutics Inc | — | NEW | New buy |
| 9 | TRVI | Trevi Therapeutics Inc | — | NEW | New buy |
| 10 | PRAX | Praxis Precision Medicines I | — | NEW | New buy |
| 11 | 260 | Centessa Pharmaceuticals-adr | — | NEW | New buy |
| 12 | ELVN | Enliven Therapeutics Inc | — | NEW | New buy |
| 13 | ✓ | Merus N V | — | NEW | New buy |
| 14 | GERN | Geron CORP | — | NEW | New buy |
| 15 | CGON | Cg Oncology Inc | — | NEW | New buy |
| 16 | ATYR | Atyr Pharma Inc | — | NEW | New buy |
| 17 | TECX | Tectonic Therapeutic Inc | — | NEW | New buy |
| 18 | XENE | Xenon Pharmaceuticals Inc | — | NEW | New buy |
| 19 | BRD1EUR | Mind Medicine Mindmed Inc | — | NEW | New buy |
| 20 | EWTX | Edgewise Therapeutics Inc | — | NEW | New buy |
| 21 | ✓ | Edgewise Therapeutics Inc | — | NEW | New buy |
| 22 | JANX | Janux Therapeutics Inc | — | NEW | New buy |
| 23 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 24 | WHWK | Whitehawk Therapeutics Inc | — | NEW | New buy |
| 25 | KRRO | Korro Bio Inc | — | NEW | New buy |
| 26 | PMNEUR | Promis Neurosciences Inc | — | NEW | New buy |
| 27 | TYRA | Tyra Biosciences Inc | — | NEW | New buy |
| 28 | CNTX | Context Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Ally Bridge Group reported a total U.S. public equity portfolio value of $113.1M across 28 disclosed positions in Q1 2025.
During Q1 2025, Ally Bridge Group's top holdings by market value included SWTXUSD (11.2%)、VRNA (8.0%)、SLNOEUR (7.8%). The largest single position, SWTXUSD, represented 11.2% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
SWTXUSD
市值: $12.4M
In Q1 2025, Ally Bridge Group made 28 total portfolio adjustments, initiating 28 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.